Ron DePinho: PACIFIC Trial Analysis on PPIs and Durvalumab Outcomes
Ron DePinho, Professor of Department of Cancer Biology, Division of Discovery Science at MD Anderson Cancer Center, shared a post on LinkedIn: “In the PACIFIC trial, durvalumab following…
Read the full articleYou might also wanna read
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study
DurHope phase 2 study: 30 HCC patients with Vp3/4 PVTT received durvalumab + HAIC-FOLFOX. Primary endpoint: 1-yr OS rate. Could this new app
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
Conditions : Biliary Tract Neoplasms Immunotherapy Interventions : Combination Product: Durvalumab plus GEMOX/GC chemotherapy sequentially f
La inmunoterapia posquirúrgica ayudó a las personas con cáncer de vejiga de riesgo alto a vivir sin cáncer por más tiempo
En un estudio del NCI, se observó que administrar pembrolizumab a los pacientes después de la cirugía para el cáncer de vejiga con invasión
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
Conditions : Esophageal Squamous Carcinoma Cell Interventions : Drug: PD-1/IL-2α-bias bispecific antibody fusion protein Sponsors : Beijing
Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer
Conditions : Rectal Cancer Patients Interventions : Drug: BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody) Sponsors : Henry Smith;
A Multicenter Randomized Open-Label Trial Evaluating MRD-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Conditions : NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Carcinoma); NSCLC;
Comments
Sign in to join the conversation.
No comments yet. Be the first.